A carregar...
Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
BACKGROUND: Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia leading to significant reductions of BCR-ABL1 transcript levels in peripheral blood. OBJECTIVE: To evaluate the response to imatinib mesylate treatment (400 mg/day) in Brazilian patients in the chronic phase o...
Na minha lista:
| Publicado no: | Rev Bras Hematol Hemoter |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Sociedade Brasileira de Hematologia e Hemoterapia
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5568590/ https://ncbi.nlm.nih.gov/pubmed/28830599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bjhh.2017.04.007 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|